An evaluation of pharmacogenomic information provided by five common drug information resources

Journal of the Medical Library Association

Volumn 102, Issue 1, 2014, Pages 47-51

  Vaughan, K T L ^a   Scolaro, Kelly L ^b   Anksorus, Heidi N ^b   Roederer, Mary W ^b  

^a JAMES MADISON UNIVERSITY   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHARMACOLOGICAL BIOMARKER;

ARTICLE; DRUG INFORMATION; DRUG LABELING; HUMAN; PHARMACOGENETICS; STATISTICS;

BIOMARKERS, PHARMACOLOGICAL; DRUG INFORMATION SERVICES; DRUG LABELING; HUMANS; PHARMACOGENETICS;

EID: 84892620652     PISSN: 15365050     EISSN: 15589439     Source Type: Journal    
DOI: 10.3163/1536-5050.102.1.009     Document Type: Article

References (20)

1. Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels [Internet]. Springfield, MD: The Administration; Jun 6 2013 [cited 25Mar 2013]., http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ ucm083378.htm.
2. Roederer MW, Van Riper M, Valgus J, Knafl G, McLeod H. Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. Per Med. 2012 Jan;9(1):19-27.
3. McCullough KB, Formea CM, Berg KD, Burzynski JA, Cunningham JL, Ou NN, Rudis MI, Stollings JL, Nicholson WT. Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ. 2011 Apr;75(3):51.
4. Thurston VC, Wales PS, Bell MA, Torbeck L, Brokaw JJ. The current status of medical genetics instruction in US and Canadian medical schools. Acad Med. 2007 May;82(5): 441-5.
5. Higgs JE, Andrews J, Gurwitz D, Payne K, Newman W. Pharmacogenetics education in British medical schools. Genomic Med. 2008 Dec;2(3):101-5.
6. Haga S, O'Daniel J, Tindall G, Lipkus I, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 2011 Jun;12(3):197-204.
7. Frueh FW, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, Verbrugge RR, Burckart GJ, Lesko LJ. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy. 2008 Aug;28(8):992-8.
8. Grice GR, Seaton TL, Woodland AM, McLeod HL. Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics. 2006 Jan;7(1):61-5.
9. International Warfarin Pharmacogenetics Consortium, Klein T, Altman R, Eriksson N, Gage B, Kimmel S, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19;360(8):753-64.
10. Epstein RS, Moyer TP, Aubert RE, Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo warfarin effectiveness study). J Am Coll Cardiol. 2010 Jun;55(25):2804-12.
11. Shin J, Kayser SR. Accuracy of the pharmacogenetic dosing table in the warfarin label in predicting initial therapeutic warfarin doses in a large, racially diverse cohort. Pharmacotherapy. 2011 Sep;31(9):863-70.
12. Stanek E, Sanders C, Taber KJ, Khalid M, Patel A, Verbrugge R, Agatep BC, Aubert RE, Epstein RS, Frueh FW. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012 Mar;91(3):450-8.
13. Zineh I, Gerhard T, Aquilante C, Beitelshees A, Beasley B, Hartzema A. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J. 2004 Dec;4(6):354-8.
14. Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelshees AL, Beasley BN, Hartzema AG. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother. 2006 Apr;40(4):639-44.
15. Wang LM, Wong M, Lightwood JM, Cheng CM. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010 Jan;44(1):28-34.
16. Polen H, Zapantis A, Clauson K, Jebrock J, Paris M. Ability of online drug databases to assist in clinical decisionmaking with infectious disease therapies. BMC Infect Dis. 2008 Nov;8(1):153.
17. Clauson KA, Marsh WA, Polen HH, Seamon MJ, Ortiz BI. Clinical decision support tools: analysis of online drug information databases. BMC Med Inform Decis Mak. 2007 Mar;7(1):7.
18. Kupferberg N, Hartel LJ. Evaluation of five full-text drug databases by pharmacy students, faculty, and librarians: do the groups agree? J Med Lib Assoc. 2004 Jan;92(1):66-71.
19. Bartholow M. Top 200 drugs of 2010. Pharm Times. 2011 May;77(5):52-9.
20. Murphy JE, Green JS, Adams LA, Squire RB, Kuo GM, McKay A. Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States. Am J Pharm Educ. 2010 Feb;74(1):7.